Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Research question Better conceptual fit Reason Isolating amylin receptor biology from calcitonin signalling Eloralintide Selective for the amylin receptor by design Studying dual amylin/calcitonin receptor pharmacology Cagrilintide DACRA profile engages both receptor families Working against the deepest published dataset Cagrilintide Phase 2 dose-finding plus a 68-week phase 3 monotherapy arm Tracking the newest clinical signal in the class Eloralintide 48-week phase 2 published in The Lancet , ObesityWeek 2025 Understanding amylin-plus-incretin combination strategy Both Cagrilintide pairs with semaglutide in CagriSema
), ,
In the 72-week non-diabetic obesity trial, adults lost -15.0% at 5 mg, -19.5% at 10 mg, and -20.9% at 15 mg. Real-world outcomes vary because dose reached, adherence, and baseline state vary
Important formulation note: Avoid Disodium EDTA and strong chelating agents in the same formula, because they can bind copper and reduce the performance of the copper peptide complex
US$ 20.01
US$ 28.53
US$ 25.55
US$ 24.25
